Literature DB >> 20221660

A case report of metastatic neuroendocrine carcinoma of the right adrenal gland successfully treated with chemotherapy and surgery.

Toshiya Ochiai1, Sosuke Komiyama, Hisashi Ikoma, Takeshi Kubota, Masayoshi Nakanishi, Daisuke Ichikawa, Shojiro Kikuchi, Hitoshi Fujiwara, Chohei Sakakura, Yukihito Kokuba, Teruhisa Sonoyama, Eigo Otsuji.   

Abstract

Poorly differentiated neuroendocrine carcinoma has a poor prognosis, especially when associated with distant metastasis. A 60-year-old man was admitted to a private hospital because of dyspnea at work in 2007. Computed tomography revealed lung infarction and a right adrenal tumor sized 12 cm in diameter that was tightly compressed against the inferior vena cava (IVC). Moreover, multiple lymph node metastases around the celiac axis and a solitary liver metastasis at the lateral segment were observed. Thus, we planned chemotherapy without surgery. We selected a combination therapy of irinotecan (CPT-11) and cisplatin (CDDP) (i.e., IP therapy): administration of CDDP [60 mg/m(2) body surface area (BSA)] on day 1 plus CPT-11 (80 mg/m(2)) BSA on days 1 and 8. Thereafter, this protocol was repeated at 3-week intervals. After 15 months of this chemotherapy strategy, the whole lesions showed a partial response by RECIST. The primary tumor had shrunk to 4.2 cm in diameter. In November 2008, we planned surgery to perform resection of the whole lesions. Histological diagnosis of the specimen was a poorly differentiated neuroendocrine carcinoma based on the immunostaining features, i.e., synaptophysin- and chromogranin positive. There were no viable tumor cells at the dissected lymph nodes or at the liver tumor. After surgery, CPT-11 administration was continued. The patient has remained well for 9 months without recurrence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20221660     DOI: 10.1007/s10147-010-0051-z

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  15 in total

Review 1.  Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options.

Authors:  R Arnold
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-08       Impact factor: 3.043

2.  Treatment of metastatic neuroendocrine carcinomas based on WHO classification.

Authors:  Salvatore Artale; Laura Giannetta; Giulio Cerea; Dario Maggioni; Paolo Pedrazzoli; Ilaria Schiavetto; Marcello Napolitano; Silvio Veronese; Emanuela Bramerio; Marcello Gambacorta; Angelo Vanzulli; Salvatore Pisconti; Raffaele Pugliese; Salvatore Siena
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

Review 3.  Irinotecan plus cisplatin in small-cell lung cancer.

Authors:  Alan Sandler
Journal:  Oncology (Williston Park)       Date:  2002-09       Impact factor: 2.990

4.  Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma.

Authors:  E Rivera; J A Ajani
Journal:  Am J Clin Oncol       Date:  1998-02       Impact factor: 2.339

5.  [A successful two-stage treatment with CDDP and CPT-11 for pancreatic neuroendocrine carcinoma with liver metastasis].

Authors:  Satoru Nomura; Akira Togawa; Takashi Kaiho; Kazuyasu Shinmura; Shinji Yanagisawa; Ryo Okamoto; Masaki Nishimura; Shun-ichi Tsuchiya; Masaru Miyazaki
Journal:  Gan To Kagaku Ryoho       Date:  2009-11

6.  Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.

Authors:  E Bajetta; L Ferrari; G Procopio; L Catena; E Ferrario; A Martinetti; M Di Bartolomeo; R Buzzoni; L Celio; M Vitali; E Beretta; E Seregni; E Bombardieri
Journal:  Ann Oncol       Date:  2002-04       Impact factor: 32.976

7.  Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

Authors:  Primo N Lara; Ronald Natale; John Crowley; Heinz Josef Lenz; Mary W Redman; Jane E Carleton; James Jett; Corey J Langer; J Philip Kuebler; Shaker R Dakhil; Kari Chansky; David R Gandara
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

Review 8.  Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.

Authors:  G A Kaltsas; J J Mukherjee; A Isidori; B Kola; P N Plowman; J P Monson; A B Grossman; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  2002-08       Impact factor: 3.478

9.  Chemotherapy with 5-fluorouracil and streptozotocin in carcinoid tumors of gastrointestinal origin: experiences with 13 patients.

Authors:  R Ridolfi; L Amaducci; S Derni; L Fabbri; M P Innocenti; P Vignutelli
Journal:  J Chemother       Date:  1991-10       Impact factor: 1.714

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  2 in total

1.  Carcinoma-like nonfunctional pheochromocytoma in the right adrenal gland: A case report.

Authors:  Shingo Moriyama; Hideki Takeshita; Saori Araki; Takuo Tokairin; Makoto Kagawa; Koji Chiba; Akiko Adachi; Akira Noro
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967

2.  An isolated metachronous metastasis to the adrenal gland from a pancreatic neuroendocrine tumor: A case report.

Authors:  Yasunaru Sakuma; Naohiro Sata; Kazuhiro Endo; Yoshikazu Yasuda; Shinichiro Yokota; Yoshinori Hosoya; Atsushi Shimizu; Hirofumi Fujii; Daisuke Matsubara; Noriyoshi Fukushima; Shoko Asakawa; Yuuki Kawarai Shimada; Chieko Kawarai Lefor; Alan Kawarai Lefor
Journal:  Int J Surg Case Rep       Date:  2017-10-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.